ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Phase 1

Completed

Conditions: Recurrent Esophageal Carcinoma
Anaplastic Astrocytoma
Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Estrogen Receptor Negative
Estrogen Receptor Positive
Glioblastoma
Hormone-Resistant Prostate Cancer
Metastatic Prostate Carcinoma
Metastatic Renal Cell Cancer

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sirolimus

First Posted Date: 2012-02-01

Last Posted Date: 2016-10-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01522820

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Phase 2

Terminated

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloblastic Leukemia With Maturation (M2)

Interventions: Dietary Supplement: cholecalciferol
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-01-31

Last Posted Date: 2015-06-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01521936

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Stage IV Pancreatic Cancer

Interventions: Drug: dovitinib lactate
Drug: gemcitabine hydrochloride
Drug: capecitabine
Other: laboratory biomarker analysis
Other: enzyme-linked immunosorbent assay
Other: pharmacological study

First Posted Date: 2011-12-22

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01497392

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

Phase 1

Completed

Conditions: Basal Cell Carcinoma of the Skin
Pain
Recurrent Skin Cancer

Interventions: Drug: methyl-5-aminolevulinate hydrochloride cream
Procedure: laser therapy
Drug: photodynamic therapy

First Posted Date: 2011-02-09

Last Posted Date: 2014-09-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01292668

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination

Not Applicable

Withdrawn

Conditions: Healthy, no Evidence of Disease

Interventions: Biological: hepatitis B antigen peptide
Other: placebo
Other: immunoenzyme technique

First Posted Date: 2011-02-09

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01292421

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

Phase 1

Withdrawn

Conditions: Refractory Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Other: laboratory biomarker analysis
Genetic: western blotting
Genetic: gene expression analysis
Other: pharmacological study
Other: flow cytometry
Genetic: fluorescence in situ hybridization
Biological: azadirachta indica
Genetic: reverse transcriptase-polymerase chain reaction

First Posted Date: 2010-12-01

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01251250

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Phase 1

Completed

Conditions: Giant Cell Glioblastoma
Gliosarcoma
Anaplastic Oligoastrocytoma
Glioblastoma
Anaplastic Oligodendroglioma
Anaplastic Astrocytoma
Mixed Glioma
Recurrent Brain Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Montanide ISA-51/Survivin Peptide Vaccine
Biological: Sargramostim

First Posted Date: 2010-11-30

Last Posted Date: 2017-02-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01250470

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Drug: cytarabine
Drug: lenalidomide

First Posted Date: 2010-11-23

Last Posted Date: 2020-09-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 32

Registration Number: NCT01246622

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Effect of a Low Glycemic Index Diet on Breast Density

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Behavioral: Low Glycemic Diet

First Posted Date: 2010-11-10

Last Posted Date: 2014-04-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 46

Registration Number: NCT01237938

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

Phase 1

Completed

Conditions: Barrett's Esophagus
CIS
HGD

Interventions: Drug: HPPH

First Posted Date: 2010-11-10

Last Posted Date: 2014-12-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01238042

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

AI-Powered Research

Premium Access

ROSWELL PARK CANCER INSTITUTE

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination

Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Effect of a Low Glycemic Index Diet on Breast Density

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus